A combination medicine that effectively manages the symptoms of allergic rhinitis such as runny & stuffed nose. Demonstrates a substantial reduction in allergic symptoms including, rhinorrhea, nasal congestion, nasal itching, and sneezing than montelukast-levocetirizine in patients with allergic rhinitis. (Mohini Sachin Mahatme, 2016) More effective agent than antihistaminic alone in the control of allergic rhinitis symptoms. (Mohini Sachin Mahatme, 2016) Has a dual mechanism of action and acts both as a bronchodilator and anti-inflammatory agent. (Mohini Sachin Mahatme, 2016) A safe and effective drug in the treatment of autumnal seasonal allergic rhinitis. (T B Casale, 1999) Significantly more effective than loratadine in relieving itchy, watery, red eyes symptoms and nasal congestion of seasonal allergic rhinitis patients. (P Van Cauwenberge, 2000)

A proton pump inhibitor, a valuable agent for the management of acid-related disorders. (Luis Moreira Dias, 2009) A potent inhibitor of gastric acid secretion by its action upon hydrogen potassium ATPase. (C J van Rensburg, 1996) A safe and effective drug for the initial treatment and maintenance therapy for the management of erosive and non-erosive GERD. (Sony Mathews, 2010) A highly effective agent with a good safety profile for long-term prophylaxis of reflux esophagitis. (J Mössner, 1997) Offers faster relief than 40 mg esomeprazole for night-time GORD symptoms. (Orr, 2005) Provides rapid relief from heartburn, acid regurgitation, and pain on swallowing in reflux esophagitis individuals. (R Corinaldesi, 1995) As effective as omeprazole in the treatment of reflux esophagitis. (R Corinaldesi M. V., 1995) Provides more rapid relief in symptoms and superior healing of erosive esophagitis than nizatidine. (T O G Kovacs 1, 2002) A highly effective first-line therapy for the management of gastroesophageal reflux disease. (D Armstrong, 2001) Significantly effective for acute and long-term treatment with excellent control of relapse and symptoms. (Carlo Calabrese, 2007) Shows superior efficacy to famotidine in ulcer healing and pain relief after 2 weeks in patients with duodenal ulcers. (A Fitton, 1996)

An immunosuppressive drug used to prevent organ rejection and treat autoimmune diseases like rheumatoid arthritis, Crohn’s disease, and multiple sclerosis. (N’ghaya Toulbe, 2022) A medication used for managing active rheumatoid arthritis and preventing kidney transplant rejection. (Oranus Mohammadi, 2023) A potent and effective drug for the treatment of numerous inflammatory dermatoses. (B B Tan, 1997) An immunosuppressant and corticosteroid-sparing medication used to treat various skin diseases. (Melissa Wise, 2007) Provides an alternative therapy for patients with psoriatic arthritis. (J C Lee, 2001) An effective treatment option for patients with complex dermatological conditions or those unresponsive to conventional therapies. (Sonia Chavez-Alvarez, 2020) Effectively reduces inflammation by blocking the immune system. (Antje Timmer, 2016) An effective treatment for maintaining remission in ulcerative colitis. (Antje Timmer, 2016) Prevents the body from attacking its tissues in autoimmune diseases and reduces the risk of organ rejection in transplants. (Antje Timmer, 2016) An effective drug for maintaining remission in patients with ulcerative colitis and reducing the need for steroids. (Toshifumi Hibi, 2003) A suitable long-term treatment for patients who can't tolerate mesalazine or sulfasalazine, or need frequent steroids. (Sonia Chavez-Alvarez, 2020)

A potent antihypertensive combination drug for effective blood pressure management and cardiovascular protection. More effective than olmesartan medoxomil 40 mg alone in reducing both systolic and diastolic blood pressure in patients with moderate to severe hypertension. (Roberto Fogari, 2010) Demonstrates superior reductions in both seated diastolic blood pressure and seated systolic blood pressure compared to monotherapy. (Steven G Chrysant, 2004) A well-tolerated drug that exhibits significant blood pressure reductions of up to 26.8/21.9 mm Hg. (Steven G Chrysant, 2004) An effective and safe agent in managing blood pressure in individuals with mild-to-severe hypertension. (Lars Christian Rump, 2010) A viable treatment option for patients struggling to achieve recommended blood pressure goals with monotherapy. (Lars Christian Rump, 2010) Shows superior efficacy in lowering blood pressure compared to the regimen of benazepril plus amlodipine besylate in patients with stage 2 hypertension. (Dean J Kereiakes, 2007) Promotes the excretion of sodium and water, thereby reducing blood volume and decreasing blood pressure. Produces greater reductions in blood pressure than a range of antihypertensive agents including other angiotensin II receptor blockers. (Ruilope, 2008) Blocks the action of angiotensin II, a substance in the body that causes blood vessels to constrict. (Julie A Brousil, 2003) Acts synergistically to lower blood pressure more effectively than either drug alone. Lowers blood pressure and protects the heart and blood vessels from damage associated with hypertension. An effective, fast-acting, and well-tolerated antihypertensive agent. (Brunner, 2006) A beneficial antihypertensive agent especially for high-risk patients. (Stefano Omboni M. V., 2019) An effective and well-tolerated combination antihypertensive therapy that results in significant BP reductions and BP control. (Greathouse, 2006)

An anti-hyperglycemic agent that is primarily used for the management of type 2 diabetes mellitus. An oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver, and muscles. (Pablos-Velasco, 2010) Improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. (Pablos-Velasco, 2010) Effectively improves blood glucose levels, long-term glucose control, and the lipid profile in patients with type 2 diabetes mellitus. (Andreas Pfützner, 2006) An attractive and effective treatment option for managing type 2 diabetes mellitus. (Andreas Pfützner, 2006) Significantly improves HbA1c and FPG while producing beneficial effects on serum lipids in patients with type 2 diabetes. (S Aronoff, 2000) Exerts additional beneficial vascular effects in patients with type 2 diabetes mellitus. (Keiichiro Harashima, 2009) A well-tolerated agent in patients with varying degrees of renal impairment. (Klemens Budde, 2003) Improves insulin resistance in Type 2 diabetes without inducing insulin secretion from pancreatic β-cells, thereby reducing the risk of hypoglycemia. (Klemens Budde, 2003) Controls blood sugar levels by increasing the body's sensitivity to insulin, a hormone that regulates glucose metabolism. Ameliorates glycaemic control, by lowering fasting and postprandial blood glucose levels, and improves insulin sensitivity. (Michaela Diamant, 2003) Alleviates insulin resistance associated with type 2 diabetes and improves hyperglycemia, reducing HbA1c levels. (Toyota, 2001) Offers an effective approach to reducing measures of cardiovascular risk and arteriosclerosis. (John Waugh, 2006) A more beneficial treatment option for managing coronary artery disease progression in individuals with type 2 diabetes. (Steven E Nissen & Investigators, 2008)

A new class of antiplatelet agents (blood thinners) keeps blood flowing smoothly in the body. (Oestreich, 2014) Prevents platelets from sticking together and lessens the formation of harmful blood clots. Maintains blood flow in the body to help reduce the risk of another cardiovascular event. Exerts a faster onset of action and more potent inhibition of platelet aggregation than clopidogrel in acute coronary syndromes patients. (Robert F. Storey, 2010) A first‐line treatment for the prevention of blood clots in adult patients with acute coronary syndromes and in coronary artery disease patients who undergo percutaneous coronary intervention. (Charalambos Vlachopoulos, 2019) Possesses superior efficacy and greater antiplatelet effect than clopidogrel in acute coronary syndromes patients. (Robert F. Storey, 2010) Shows a significant improvement in aortic stiffness in patients with coronary artery disease. (Charalambos Vlachopoulos, 2019) Diminishes the rate of stroke, cardiovascular death, and myocardial infarction in subjects with acute coronary syndrome or a history of myocardial infarction.

A dipeptidyl peptidase-4 (DPP-4) inhibitor that treats patients with type 2 diabetes mellitus. (Sheridan Henness, 2006) Improves glycaemic control in type 2 diabetes by inhibiting DPP-4. (Sheridan Henness, 2006) A well-tolerated and efficacious antidiabetic drug in reducing glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose levels. (Prato, 2007) Enhances beta-cell functionality in diabetic patients by boosting insulin secretion. (A Mari, 2005) A safe therapeutic option for managing patients with type 2 diabetes mellitus. (Chantal Mathieu, 2017) Improves the sensitivity and responsiveness of pancreatic α-cells and β-cells to glucose. (Dejager, 2013) An efficacious and safe treatment both as monotherapy and in combination with metformin. (Matthias Blüher, 2012) Effectively improves blood sugar control in a broad range of T2DM patients, including those with impaired glucose tolerance and advanced disease requiring insulin therapy. (Degrande, 2008) An effective and well-tolerated for patients with type 2 diabetes mellitus who have inadequate control with metformin monotherapy. (M Goodman, 2009) A potentially beneficial treatment option for patients with type 2 diabetes due to its inhibition of DPP-4, leading to increased levels of incretin hormones. (Yan-Ling He, 2007)

A proton pump inhibitor is employed in the management and treatment of numerous gastrointestinal diseases. (Shah & Gossman, 2020) Blocks the release of acid and decreases the acidity inside the stomach. The best pharmacological option for controlling gastric acid secretion in Zollinger-Ellison syndrome patients. (D McTavish, 1991) Superior to ranitidine in keeping patients with erosive reflux esophagitis in remission over 12 months. (B Hallerbäck, 1994) A well-tolerated agent that effectively eradicates Helicobacter pylori infection in adults or children. (H D Langtry, 1998) Provides more rapid and complete healing compared with ranitidine, cimetidine in patients with duodenal or gastric ulcers. (D McTavish, 1991) Has a rapid and long-lasting effect on acid secretion and acid-induced symptoms in Zollinger-Ellison syndrome subjects. (Walan, 1989) Superior to cimetidine for the relief of all grades of heartburn in gastro-esophageal reflux disease. (C M Bate, 1997) A highly effective drug in healing ulcers that have failed to respond to histamine type 2 blockers. (Howden, 1991) Gives significantly higher healing rates than ranitidine  in patients with severe gastroesophageal reflux disease. (M Iskedjian, 1998)

An antipsychotic agent for the treatment of mental illnesses such as schizophrenia, manic episodes (irritable mood, having suicidal thoughts), and other psychotic disorders An effective antipsychotic agent that improves negative as well as positive symptoms of schizophrenia. (Cohen, 1994) A better-tolerated and more effective in a subset of patients with treatment-refractory schizophrenia. (D A Wirshing, 1999) Alleviates the symptoms of various mood disorders by affecting the levels of chemical messengers such as dopamine and serotonin. An effective anticholinergic agent that provides relief from neuroleptic-induced extrapyramidal symptoms in psychiatric patients. (Pankaj Mahal, 2018) More efficacious than typical antipsychotics in the treatment of schizophrenia. (Jennifer M Rendell, 2006) Provides a faster decrease in the severity of bipolar symptoms. (Carlene M MacMillan, 2008) Demonstrates a rapid onset of action and effectively reduces the symptoms of acute mania. (Robert M A Hirschfeld, 2004) More effective than conventional antipsychotics in treating positive and negative symptoms. (John M Davis, 2002) Provides sustained improvement in symptoms as well as global functioning in schizophrenia individuals. (Gahan Pandina, 2012)

A dietary supplement that is used in the treatment of arthralgia (joint pain), and swelling. Stops the degradation of cartilage and restores lost cartilage. (Jasvinder A Singh, 2015) Reduces friction in the joints and provides comfort during physical movements. (Jasvinder A Singh, 2015) Delays further cartilage degradation and forms a protective layer between joints to relieve pain. A promising therapeutic agent that acts as a lubricant, shock absorber, and joint structure stabilizer. (Ramesh C. Gupta, 2019) Prevents cartilage denaturation, protects the outer layer of cartilage, blocks synovial inflammation, increases chondrocyte density, and promotes synovium metabolism. (Mariko Oe, 2016) Reduces pro-inflammatory marker activity, decreases apoptosis, and stimulates the production of collagen and proteoglycan. (Burton Dunlap, 2021) Contains sulfur‐containing amino acids, which are essential building blocks for cartilage molecules in the human body. (Jasvinder A Singh, 2015) Prevents joint space narrowing and reduces joint swelling and effusion. (M Iovu, 2008) A safe and effective treatment that reduces pain and lubricates the joints in osteoarthritis patients. A potential option to prevent joint destruction, pain, and loss of function in osteoarthritis patients. (Fulya Bakilan, 2016) A valuable therapeutic tool that offers protection from oxidative free-radical damage. (Yves Henrotin, 2010) A beneficial therapeutic product for the management of knee osteoarthritis. (Yves Henrotin, 2010) A powerful antioxidant that fights molecules that trigger joint inflammation. Prevents inflammatory arthritis and maintains healthy joints in patients with osteoarthritis. (Umberto Ripani, 2019)

A nutritional supplement that treats neuropathic pain, and manages all diabetes and cardiovascular complications. An appropriate option to cure anemias and nerve problems. Exerts neuronal protection by promoting the regeneration of injured nerves. (Ming Zhang, 2013) Helps in repairing nerve function and decreasing oxidative stress. An effective drug in improving the symptoms of neuropathy and promotes the injured nerve’s regeneration. (Ming Zhang W. H., 2013) Prevents the progression of diabetic complications. (Marie-Laure Volvert, 2008) A promising therapy for the treatment of impaired diabetic neuropathic conditions associated with pain. (D. Vasudevan, 2014) An effective therapy for reduction in triglycerides, total and low-density lipoprotein cholesterol levels. (Reza Tabrizi, 2018) Reverses peripheral diabetic neuropathy through its multiple antioxidant properties. (Natalia Vallianou, 2009) A potential candidate for treating peripheral neuropathy with good safety. (Ming Zhang W. H., 2013) An effective medication in lowering both fasting blood glucose and HbA1c levels in type 2 diabetes patients. (Basilio Pintaudi, 2016)

A dual-action drug that acts as an airway mucus regulator and a bronchodilator. (Pozzi, 2007) Effective in lessening the frequency of episodes of bronchial obstruction. (Ajitha Sharma, 2014) Facilitates the muscles of the airways to relax and expel out mucus. (Ajitha Sharma, 2014) Possesses anti-inflammatory properties that help in clearing the inflammation of the lung airways. (Ajitha Sharma, 2014) Increases mucociliary clearance by augmenting ciliary motility in chronic obstructive pulmonary. (Sumit Roy Tapadar, 2014) Significantly decreases the amount of sputum and reduces airway obstruction. (Pozzi E. , 2007) Has the potential to limit the frequency of relapses of infection in bronchial obstruction. Lessens the need for beta2-agonists. (Gangajalia, 2019) More active than ambroxol as it reduces episodes of bronchospasm attack. (Dr. Kamlesh Kumar Pandey, 2019) A safer drug than theophylline in terms of cardiovascular and central nervous system-related side effects. (Dr. Kamlesh Kumar Pandey, 2019)

An ayurvedic female uterine tonic treats menstrual irregularities, uterine disorders, heavy bleeding, gynecological disorders. A potent herbal medicine used to support the proper functioning of the genitourinary tract. (Saurabh Chhatre, 2014) A beneficial syrup for the treatment of a wide variety of gynecological problems. (Baranwal, 2014) Improves stamina in women with menstrual irregularities such as dysmenorrhea and menorrhagia. Provides nutritional support to the uterus and maintains endometrial health. Supports the healthy production of estrogen and progesterone in the female body and prevents menstrual irregularity. Effectively treats irregular menstrual cycles, amenorrhea, leucorrhea, fibroids, and other reproductive disorders. Gives relief from menstrual cramps and period pains in women. A promising therapy that treats polycystic ovary syndrome and infertility. Effective therapy for all feminine complaints and general debility. Ameliorates female reproductive health complications including hormonal imbalance, polycystic ovarian syndrome, and infertility. (Ajai K Pandey, 2018)

A lipid-lowering agent that reduces the amount of cholesterol found in the blood. The most potent statin that significantly reduces total cholesterol, triglyceride, and low-density lipoprotein cholesterol in hypercholesterolemia patients. (Chumpol Piamsomboon 1, 2002) Effectively increases high-density lipoprotein-cholesterol in patients with a wide variety of dyslipidaemias. (H S Malhotra, 2001) Lowers the risk of cardiovascular disease and helps prevent strokes and heart attacks. An appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of coronary heart disease. (H S Malhotra, 2001) More efficacious than lovastatin, pravastatin, fluvastatin, and simvastatin in achieving target low-density lipoprotein-cholesterol levels in patients with coronary heart disease. (H S Malhotra, 2001) Shows a greater reduction of serum total cholesterol, low-density lipoprotein cholesterol, triglyceride concentrations, and apolipoprotein B-100 compared with pravastatin, simvastatin, or lovastatin. (H S Yee, 1998)

An antivertigo drug that is used in the management of vertigo and vestibular pathologies of different aetiologies. (Lacour, 2013) Significantly effective in preventing/reversing the hearing deterioration in patients with Meniere’s disease. (Seyed Javad Seyed Tootoonchi, 2016) Exerts a positive effect in terms of reduction in vertigo symptoms. (Louisa Murdin K. H., 2016) An effective therapy for Meniere’s disease and related conditions. (Van Esch B, 2020) Improves the symptoms related to Meniere’s disease, such as vertigo sensation. Effectively reduces the pressure and ameliorates the blood flow to certain areas within the inner ear. (Deborah A Hall, 2018) Reduces the frequency and severity of vertiginous episodes, hearing loss, and tinnitus. (Cochrane ENT Group, 2001) Arrests the progression of hearing loss in patients with Meniere’s syndrome. (Cochrane ENT Group, 2001) An effective and safe option for the treatment of peripheral vertigo. (Rubén Ramos Alcocer, 2015)

A lipid-lowering agent that is used in the treatment of high levels of fats. A highly effective drug in reducing low-density lipoprotein cholesterol, and increasing high-density lipoprotein cholesterol. (Anders G Olsson, 2002) More effective than other statins in reducing low-density lipoprotein, triglyceride, and total cholesterol levels. (Michael F Bullano, 2006) Improves cholesterol levels which prevent blockages from forming in arteries. Lessens the risk of cardiovascular events and stabilizes atherosclerosis. (Toth, 2014) A cost-effective statin option in treating low-density lipoprotein cholesterol goals in patients with hypercholesterolemia. (Mark Hirsch, 2005) A valuable addition to the statin drug class. (Cheng-Lai, 2003)

An anti-diabetic drug that reduces glycemia in patients with type 2 diabetes mellitus. (B Ahrén, 2011) Enhances pancreatic islet cell responsiveness to glucose. (Degrande, 2008) Improves the impaired sensitivity of the beta cells to glucose. (Foley, 2019) A well-tolerated and efficacious medicine in improving glycemic control in patients with type 2 diabetes mellitus. (Degrande, 2008) An effective therapy for glycemic control with a low risk of hypoglycemia. (L Cai, 2012) A safe and effective therapeutic option for patients with type 2 diabetes mellitus, both as monotherapy and as an add-on treatment. (Eleni Bekiari, 2016) A safe option for managing patients with type 2 diabetes mellitus. (Chantal Mathieu, 2017) An efficacious candidate in reducing glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose levels. (Prato, 2007) An important choice for use in combination with metformin, a sulfonylurea, or a thiazolidinedione in patients with type 2 diabetes who require combination therapy. (Keating, 2010) An attractive therapeutic option in patients where metformin monotherapy alone is not sufficient. (Thomas Forst, 2014) More effective in decreasing HbA1c and enables patients to reach glycemic control than sitagliptin, and linagliptin. (Yun-Zhao Tang, 2015)